Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.

Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L, Covey A, Karrasch M, Getrajdman G, Mescheder A, Jarnagin W, Kemeny N.

Mol Ther. 2009 Feb;17(2):389-94. doi: 10.1038/mt.2008.240. Epub 2008 Nov 18.

2.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Dec;16(12):1910-8. doi: 10.1038/mt.2008.212. Epub 2008 Sep 30.

3.

Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort.

Goldsby R, Burke C, Nagarajan R, Zhou T, Chen Z, Marina N, Friedman D, Neglia J, Chuba P, Bhatia S.

Cancer. 2008 Nov 1;113(9):2597-604. doi: 10.1002/cncr.23860.

5.

Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.

Duerner LJ, Schwantes A, Schneider IC, Cichutek K, Buchholz CJ.

Gene Ther. 2008 Nov;15(22):1500-10. doi: 10.1038/gt.2008.92. Epub 2008 May 29.

PMID:
18509380
6.

Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, Barber GN, Hall G, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Jul;16(7):1217-26. doi: 10.1038/mt.2008.83. Epub 2008 Apr 22.

7.

Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.

Currier MA, Gillespie RA, Sawtell NM, Mahller YY, Stroup G, Collins MH, Kambara H, Chiocca EA, Cripe TP.

Mol Ther. 2008 May;16(5):879-85. doi: 10.1038/mt.2008.49. Epub 2008 Mar 25.

8.

Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Mahller YY, Vaikunth SS, Ripberger MC, Baird WH, Saeki Y, Cancelas JA, Crombleholme TM, Cripe TP.

Cancer Res. 2008 Feb 15;68(4):1170-9. doi: 10.1158/0008-5472.CAN-07-2734.

9.

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.

Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E.

Clin Cancer Res. 2007 Dec 1;13(23):7155-65.

10.

Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B.

J Natl Cancer Inst. 2007 Dec 5;99(23):1768-81. Epub 2007 Nov 27.

PMID:
18042934
11.

Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.

Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL.

Cancer Res. 2007 Oct 1;67(19):9371-9.

12.

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM.

Clin Cancer Res. 2007 Jul 1;13(13):3942-50.

13.

Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.

Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore SG, Rausen AR, Vietti TJ, Grier HE.

Pediatr Blood Cancer. 2007 Dec;49(7):894-900.

PMID:
17584910
14.

Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma.

Yu Z, Li S, Huang YY, Fong Y, Wong RJ.

Cancer Gene Ther. 2007 Aug;14(8):738-47. Epub 2007 May 25.

PMID:
17525764
15.

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

Power AT, Bell JC.

Mol Ther. 2007 Apr;15(4):660-5. Epub 2007 Jan 30. Review.

16.

Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.

Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, Knoll A, Getrajdman G, Kowal KJ, Jarnagin WR, Fong Y.

Hum Gene Ther. 2006 Dec;17(12):1214-24.

PMID:
17107303
17.
18.
19.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G.

J Biol Chem. 2006 Jan 13;281(2):951-61. Epub 2005 Nov 7.

20.

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.

Benencia F, Courreges MC, Conejo-GarcĂ­a JR, Buckanovich RJ, Zhang L, Carroll RH, Morgan MA, Coukos G.

Hum Gene Ther. 2005 Jun;16(6):765-78.

PMID:
15960607

Supplemental Content

Support Center